BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion. Under the terms of the ...

The African Pharmaceutical Market is projected to grow at an impressive CAGR of 6-8% by 2029, driven by a booming population, ...

Read about BioNTech SE ADR (BNTX:XNAS) stock and today's latest news and financial updates.